Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor testing cost-effective for triage to germline testing in HGSOC patients

Key clinical point: Tumor testing for triage of HGSOC patient to confirmatory genetic testing may be cost-effective.

Major finding: Tumor testing yields an incremental cost-effectiveness ratio (ICER) of $127,000 per year of life gained.

Study details: A cost-efficacy analysis.

Disclosures: Dr. Kwon has received research funding from AstraZeneca.

Citation:

Kwon J et al. SGO 2019: Abstract 5.